Ascendiant Capital Markets set a $1.00 price target on Hemispherx BioPharma (NYSEAMERICAN:HEB) in a research note released on Friday, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
HEB stock opened at $0.14 on Friday. Hemispherx BioPharma has a one year low of $0.13 and a one year high of $0.35.
Hemispherx BioPharma (NYSEAMERICAN:HEB) last released its quarterly earnings results on Monday, April 1st. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.04. The firm had revenue of $0.24 million for the quarter.
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Read More: Limitations of the P/E Growth ratio
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.